Published in Neuropharmacology on December 31, 2015
Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet (2008) 12.18
Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature (2011) 10.16
Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell (1999) 4.93
Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell (2011) 4.58
Mouse behavioral tasks relevant to autism: phenotypes of 10 inbred strains. Behav Brain Res (2006) 4.15
Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci U S A (2010) 4.02
Triadic model of the neurobiology of motivated behavior in adolescence. Psychol Med (2006) 3.62
Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry (2009) 3.24
Oxytocin increases retention of social cognition in autism. Biol Psychiatry (2006) 2.94
Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Transl Med (2012) 2.70
Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther (2003) 2.44
Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology (2003) 2.21
Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology (2009) 2.10
Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice. Psychoneuroendocrinology (2013) 1.96
A mouse model system for genetic analysis of sociability: C57BL/6J versus BALB/cJ inbred mouse strains. Biol Psychiatry (2005) 1.94
Insights into Autism Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci. Neuron (2015) 1.91
Social approach and repetitive behavior in eleven inbred mouse strains. Behav Brain Res (2008) 1.86
Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles. Biol Psychiatry (2012) 1.84
Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry (2010) 1.81
Development of a mouse test for repetitive, restricted behaviors: relevance to autism. Behav Brain Res (2007) 1.71
Rewards, aversions and affect in adolescence: emerging convergences across laboratory animal and human data. Dev Cogn Neurosci (2011) 1.61
Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res (2004) 1.56
Social approach-avoidance behavior of inbred mouse strains towards DBA/2 mice. Brain Res (2004) 1.54
Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res (2011) 1.49
Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. Transl Psychiatry (2011) 1.40
Exogenous and evoked oxytocin restores social behavior in the Cntnap2 mouse model of autism. Sci Transl Med (2015) 1.37
Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism (2012) 1.30
Social deficits, stereotypy and early emergence of repetitive behavior in the C58/J inbred mouse strain. Behav Brain Res (2009) 1.27
Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology (2001) 1.25
Density and function of central serotonin (5-HT) transporters, 5-HT1A and 5-HT2A receptors, and effects of their targeting on BTBR T+tf/J mouse social behavior. J Neurochem (2010) 1.24
Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial. J Autism Dev Disord (2014) 1.16
Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology (2009) 1.12
The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Mol Psychiatry (2015) 1.11
Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. Psychopharmacology (Berl) (2005) 1.10
Fluoxetine but not risperidone increases sociability in the BTBR mouse model of autism. Pharmacol Biochem Behav (2010) 1.10
Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology (2011) 1.10
Effects of single dose intranasal oxytocin on social cognition in schizophrenia. Schizophr Res (2013) 1.09
NMDA receptor subunit mutations in neurodevelopmental disorders. Curr Opin Pharmacol (2014) 1.08
Neuroligin-1 controls synaptic abundance of NMDA-type glutamate receptors through extracellular coupling. Proc Natl Acad Sci U S A (2012) 1.07
Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. Pharmacol Biochem Behav (2006) 1.06
Improving social perception in schizophrenia: the role of oxytocin. Schizophr Res (2013) 1.06
The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophr Res (2009) 1.04
Chronic and acute intranasal oxytocin produce divergent social effects in mice. Neuropsychopharmacology (2013) 1.03
Mice with reduced NMDA receptor expression: more consistent with autism than schizophrenia? Genes Brain Behav (2012) 1.00
Knockout of NMDA receptors in parvalbumin interneurons recreates autism-like phenotypes. Autism Res (2013) 0.99
Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders. Pediatrics (2012) 0.99
Adolescent oxytocin exposure causes persistent reductions in anxiety and alcohol consumption and enhances sociability in rats. PLoS One (2011) 0.95
Prosocial effects of oxytocin in two mouse models of autism spectrum disorders. Neuropharmacology (2013) 0.94
NMDA receptor dysfunction in autism spectrum disorders. Curr Opin Pharmacol (2015) 0.94
Parvalbumin cell ablation of NMDA-R1 causes increased resting network excitability with associated social and self-care deficits. Neuropsychopharmacology (2014) 0.94
Oxytocin administration enhances controlled social cognition in patients with schizophrenia. Psychoneuroendocrinology (2014) 0.93
Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays. J Neural Transm (Vienna) (2008) 0.91
Dose-dependent effects of chronic central infusion of oxytocin on anxiety, oxytocin receptor binding and stress-related parameters in mice. Psychoneuroendocrinology (2014) 0.91
Shank3 deficiency induces NMDA receptor hypofunction via an actin-dependent mechanism. J Neurosci (2013) 0.91
Repetitive behavior profile and supersensitivity to amphetamine in the C58/J mouse model of autism. Behav Brain Res (2013) 0.88
NMDA receptor-deficient mice display sexual dimorphism in the onset and severity of behavioural abnormalities. Genes Brain Behav (2014) 0.87
A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis. Schizophr Bull (2014) 0.85
Further characterization of repetitive behavior in C58 mice: developmental trajectory and effects of environmental enrichment. Behav Brain Res (2012) 0.85
Long-term exposure to intranasal oxytocin in a mouse autism model. Transl Psychiatry (2014) 0.85
Preweaning sensorimotor deficits and adolescent hypersociability in Grin1 knockdown mice. Dev Neurosci (2012) 0.84
The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating. Eur Neuropsychopharmacol (2011) 0.84
Altered expression of Alzheimer's disease-related genes in the cerebellum of autistic patients: a model for disrupted brain connectome and therapy. Cell Death Dis (2014) 0.83
Antipsychotic medication and social cue recognition in chronic schizophrenia. Psychiatry Res (2010) 0.83
The effects of an acute challenge with the NMDA receptor antagonists, MK-801, PEAQX, and ifenprodil, on social inhibition in adolescent and adult male rats. Psychopharmacology (Berl) (2013) 0.82
Adolescent exposure to oxytocin, but not the selective oxytocin receptor agonist TGOT, increases social behavior and plasma oxytocin in adulthood. Horm Behav (2014) 0.82
Review of the evidence for treatment of children with autism with selective serotonin reuptake inhibitors. J Spec Pediatr Nurs (2009) 0.81
Making progress in autism drug discovery. Expert Opin Drug Discov (2014) 0.81
Effects of prefrontal cortex and hippocampal NMDA NR1-subunit deletion on complex cognitive and social behaviors. Brain Res (2014) 0.81
Oxytocin reduces amygdala activity, increases social interactions, and reduces anxiety-like behavior irrespective of NMDAR antagonism. Behav Neurosci (2015) 0.78
Diazepam improves aspects of social behaviour and neuron activation in NMDA receptor-deficient mice. Genes Brain Behav (2014) 0.78
Schizophrenia and alcohol dependence: diverse clinical effects of oxytocin and their evolutionary origins. Brain Res (2014) 0.76
Repetitive behavior profile and supersensitivity to amphetamine in the C58/J mouse model of autism. Behav Brain Res (2013) 0.88